Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nausea and Vomiting, Postoperative Clear all
Completed Phase 3 Interventional Results available

US Phase III Study of APD421 in PONV

NCT01991860
View directory record Official record
Conditions
PONV
Interventions
APD421- Amisulpride for IV injection, Placebo
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jun 11, 2026, 5:32 AM EDT
Completed No phase listed Observational

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

NCT00514878
View directory record Official record
Conditions
Nausea, Postoperative Nausea and Vomiting, Postdischarge Nausea and Vomiting, Postoperative Pain
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2009 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jun 11, 2026, 5:32 AM EDT
Completed No phase listed Observational

Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing Tonsillectomy

NCT01669993
View directory record Official record
Conditions
Tonsillectomy Postoperative Adverse Events
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

NCT00952133
View directory record Official record
Conditions
PONV
Interventions
Palonosetron only, Palonosetron with Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

NCT00878228
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jun 11, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

Post-Operative Therapy for Nausea or Vomiting

NCT03075163
View directory record Official record
Conditions
Vomiting, Nausea
Interventions
Acupressure, Ondansetron
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Aromatherapy in Total Knee Replacement

NCT06045078
View directory record Official record
Conditions
Total Knee Replacement, Post-operative Nausea and Vomiting, Opioid Use, Anxiety, Depression, Post Operative Pain
Interventions
Elequil Lavender-peppermint Aromatabs, Elequil Almond-Oil Aromatabs
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

NCT02625181
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
Procedure · Device · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
27,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection

NCT00273377
View directory record Official record
Conditions
Surgical Wound Infection, Surgery, Colon
Interventions
Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg), Supplemental oxygen (80% vs. 30%), Dexamethasone, Placebo
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Results available

A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)

NCT00819039
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Ondansetron
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Food Related Video and the Incidence of Postoperative Nausea and Vomiting

NCT04719910
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Visual exposure to taped food preparation, Visual exposure to topics not related to food
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Jun 11, 2026, 5:32 AM EDT
Not listed Not applicable Interventional

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

NCT00835965
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Dexamethasone, Aprepitant, Placebo Dexamethasone
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jun 11, 2026, 5:32 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.

NCT04810494
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

NCT00326248
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
GW679769 (casopitant)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
26
States / cities
Montgomery, Alabama • Sheffield, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jun 11, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional

Developing Individualized Strategies to Prevent Nausea and Vomiting

NCT01393288
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Genetic Polymorphisms
Interventions
Ondansetron, Lorazepam, Aprepitant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
San Francisco, California • Kansas City, Kansas • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

NCT00600990
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW597599
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

NCT01510379
View directory record Official record
Conditions
Nausea and Vomiting Post-foregut Surgery
Interventions
Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge
Device · Drug
Lead sponsor
Kyle A Perry
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00659737
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

NCT05676294
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients

NCT01280331
View directory record Official record
Conditions
Postoperative Pain
Interventions
Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
Drug
Lead sponsor
QRxPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anaheim, California • Owings Mills, Maryland • Pasadena, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

NCT02473042
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting, Breast Cancer
Interventions
Electrical Stimulation, Zofran, Dexamethasone, Phenergan, Pepcid, Questionnaire
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 11, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients

NCT00757822
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Dronabinol, Ondansetron
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Jun 11, 2026, 5:32 AM EDT